aTyr Pharma (LIFE) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
August 15, 2022 4:00 PM EDTFirst sites initiated in Phase 3 EFZO-FIT study in patients with pulmonary sarcoidosis.
FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis.
Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments.
Company to host conference call and webcast today, May 15th, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery... More
